EE200000321A - Novel compounds - Google Patents

Novel compounds

Info

Publication number
EE200000321A
EE200000321A EEP200000321A EEP200000321A EE200000321A EE 200000321 A EE200000321 A EE 200000321A EE P200000321 A EEP200000321 A EE P200000321A EE P200000321 A EEP200000321 A EE P200000321A EE 200000321 A EE200000321 A EE 200000321A
Authority
EE
Estonia
Prior art keywords
novel compounds
novel
compounds
Prior art date
Application number
EEP200000321A
Other languages
Estonian (et)
Inventor
Baxter Andrew
Cheshire David
Mcinally Thomas
Mortimore Michael
Cladingboel David
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Publication of EE200000321A publication Critical patent/EE200000321A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EEP200000321A 1997-12-05 1998-12-01 Novel compounds EE200000321A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704546A SE9704546D0 (en) 1997-12-05 1997-12-05 Novel compounds
PCT/SE1998/002190 WO1999029686A1 (en) 1997-12-05 1998-12-01 Novel compounds

Publications (1)

Publication Number Publication Date
EE200000321A true EE200000321A (en) 2001-08-15

Family

ID=20409283

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000321A EE200000321A (en) 1997-12-05 1998-12-01 Novel compounds

Country Status (16)

Country Link
EP (1) EP1037889A1 (en)
JP (1) JP2001525406A (en)
KR (1) KR20010032800A (en)
CN (1) CN1284074A (en)
AU (1) AU1791599A (en)
BR (1) BR9813378A (en)
CA (1) CA2312357A1 (en)
EE (1) EE200000321A (en)
HU (1) HUP0100731A3 (en)
IL (1) IL136368A0 (en)
NO (1) NO20002787L (en)
PL (1) PL340837A1 (en)
SE (1) SE9704546D0 (en)
SK (1) SK8442000A3 (en)
TR (1) TR200001544T2 (en)
WO (1) WO1999029686A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901875D0 (en) * 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
SE9904505D0 (en) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
SE9904652D0 (en) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
JP2002330787A (en) * 2000-10-21 2002-11-19 Astrazeneca Ab Chemical substance
PA8557501A1 (en) 2001-11-12 2003-06-30 Pfizer Prod Inc BENZAMIDA, HETEROARILAMIDA AND INVESTED AMIDAS
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8591801A1 (en) 2002-12-31 2004-07-26 Pfizer Prod Inc BENZAMID INHIBITORS OF THE P2X7 RECEIVER.
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
JP4731468B2 (en) 2003-05-12 2011-07-27 ファイザー・プロダクツ・インク Benzamide inhibitor of P2X7 receptor
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
CA2571124A1 (en) 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h`1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
JP5306987B2 (en) 2006-03-16 2013-10-02 エボテック (ユーエス) インコーポレイテッド Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
TWI464148B (en) 2006-03-16 2014-12-11 Evotec Us Inc Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
DK1937643T3 (en) 2006-03-16 2016-10-10 Second Genome Inc Bicycloheteroarylforbindelser som p2x7-modulatorer og anvendelser deraf
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
GB0613473D0 (en) * 2006-07-06 2006-08-16 Glaxo Group Ltd Novel compounds
DK2049478T3 (en) 2006-07-06 2012-07-09 Glaxo Group Ltd Substituted N-phenylmethyl-5-oxoproline-2-amides as P2X7 receptor antagonists and methods for their use
WO2008112205A1 (en) 2007-03-09 2008-09-18 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
JP2010522711A (en) * 2007-03-28 2010-07-08 グラクソ グループ リミテッド Piperidinone carboxamide derivatives as P2X7 modulators
EP2139875A2 (en) * 2007-03-29 2010-01-06 Glaxo Group Limited Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators
JP2010523524A (en) * 2007-04-03 2010-07-15 グラクソ グループ リミテッド Imidazolidinecarboxamide derivatives as P2X7 modulators
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
GB0803729D0 (en) * 2008-02-29 2008-04-09 Ge Healthcare Ltd Imaging the central nervous system
DK2105164T3 (en) 2008-03-25 2011-03-21 Affectis Pharmaceuticals Ag New P2X7R antagonists and their use
EA201101479A1 (en) 2009-04-14 2012-05-30 Эффектис Фармасьютиклз Аг NEW P2X7R ANTAGONISTS AND THEIR APPLICATION
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
WO2011141194A1 (en) 2010-05-14 2011-11-17 Affectis Pharmaceuticals Ag Novel methods for the preparation of p2x7r antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CN111372555A (en) 2017-11-21 2020-07-03 3M创新有限公司 Water-in-bag plant-based oil emulsion for oral cavity and use method thereof
US11324681B2 (en) 2017-12-20 2022-05-10 3M Innovative Properties Company Oral compositions and methods of use
EP3727336A1 (en) 2017-12-20 2020-10-28 3M Innovative Properties Company Oral compositions and methods of use

Also Published As

Publication number Publication date
JP2001525406A (en) 2001-12-11
IL136368A0 (en) 2001-06-14
CA2312357A1 (en) 1999-06-17
NO20002787L (en) 2000-08-01
PL340837A1 (en) 2001-02-26
BR9813378A (en) 2000-10-10
SK8442000A3 (en) 2001-01-18
NO20002787D0 (en) 2000-05-31
HUP0100731A2 (en) 2002-05-29
CN1284074A (en) 2001-02-14
TR200001544T2 (en) 2000-11-21
EP1037889A1 (en) 2000-09-27
WO1999029686A1 (en) 1999-06-17
SE9704546D0 (en) 1997-12-05
AU1791599A (en) 1999-06-28
KR20010032800A (en) 2001-04-25
HUP0100731A3 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
PT860428E (en) PYRIMIDION COMPOUNDS
IS5479A (en) compounds
IS5478A (en) compounds
IS5477A (en) compounds
EE200000321A (en) Novel compounds
EE200000044A (en) New compounds
ID22850A (en) PIRAZINA COMPOUNDS
NO994877D0 (en) Calcilitic compounds
ID20323A (en) TRIAZINILAMINOSTILBENA COMPOUNDS
NO994900D0 (en) compounds
NO995404D0 (en) compounds
NO996544D0 (en) compounds
ID22983A (en) FLUOROMETOXIMINO COMPOUNDS
NO995007D0 (en) compounds
DE69737634D1 (en) INSECTICID OXADIAZIN COMPOUNDS
SE9702775D0 (en) Novel compounds
SE9701766D0 (en) Novel compounds
SE9701099D0 (en) Novel compounds
SE9704402D0 (en) Novel compounds
SE9702199D0 (en) Novel compounds
SE9704403D0 (en) Novel compounds
SE9702200D0 (en) Novel compounds
SE9702197D0 (en) Novel compounds
SE9701767D0 (en) Novel compounds
SE9701098D0 (en) Novel compounds